Literature DB >> 17959678

Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with lactate dehydrogenase-elevating virus.

Shelly J Robertson1, Christoph G Ammann, Ronald J Messer, Aaron B Carmody, Lara Myers, Ulf Dittmer, Savita Nair, Nicole Gerlach, Leonard H Evans, William A Cafruny, Kim J Hasenkrug.   

Abstract

Friend virus (FV) and lactate dehydrogenase-elevating virus (LDV) are endemic mouse viruses that can cause long-term chronic infections in mice. We found that numerous mouse-passaged FV isolates also contained LDV and that coinfection with LDV delayed FV-specific CD8(+) T-cell responses during acute infection. While LDV did not alter the type of acute pathology induced by FV, which was severe splenomegaly caused by erythroproliferation, the immunosuppression mediated by LDV increased both the severity and the duration of FV infection. Compared to mice infected with FV alone, those coinfected with both FV and LDV had delayed CD8(+) T-cell responses, as measured by FV-specific tetramers. This delayed response accounted for the prolonged and exacerbated acute phase of FV infection. Suppression of FV-specific CD8(+) T-cell responses occurred not only in mice infected concomitantly with LDV but also in mice chronically infected with LDV 8 weeks prior to infection with FV. The LDV-induced suppression was not mediated by T regulatory cells, and no inhibition of the CD4(+) T-cell or antibody responses was observed. Considering that most human adults are carriers of chronically infectious viruses at the time of new virus insults and that coinfections with viruses such as human immunodeficiency virus and hepatitis C virus are currently epidemic, it is of great interest to determine how infection with one virus may impact host responses to a second infection. Coinfection of mice with LDV and FV provides a well-defined, natural host model for such studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17959678      PMCID: PMC2224392          DOI: 10.1128/JVI.01413-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Enzymatic determination of transmissible replicating factors associated with mouse tumors.

Authors:  V RILEY
Journal:  Ann N Y Acad Sci       Date:  1963-02-15       Impact factor: 5.691

2.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome.

Authors:  Christian Drosten; Stephan Günther; Wolfgang Preiser; Sylvie van der Werf; Hans-Reinhard Brodt; Stephan Becker; Holger Rabenau; Marcus Panning; Larissa Kolesnikova; Ron A M Fouchier; Annemarie Berger; Ana-Maria Burguière; Jindrich Cinatl; Markus Eickmann; Nicolas Escriou; Klaus Grywna; Stefanie Kramme; Jean-Claude Manuguerra; Stefanie Müller; Volker Rickerts; Martin Stürmer; Simon Vieth; Hans-Dieter Klenk; Albert D M E Osterhaus; Herbert Schmitz; Hans Wilhelm Doerr
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

3.  Different H-2 subregions influence immunization against retrovirus and immunosuppression.

Authors:  R P Morrison; P L Earl; J Nishio; D L Lodmell; B Moss; B Chesebro
Journal:  Nature       Date:  1987 Oct 22-28       Impact factor: 49.962

4.  Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex.

Authors:  B Chesebro; K Wehrly
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

5.  Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens.

Authors:  B Chesebro; K Wehrly; M Cloyd; W Britt; J Portis; J Collins; J Nishio
Journal:  Virology       Date:  1981-07-15       Impact factor: 3.616

6.  Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses.

Authors:  Georg M Lauer; Tam N Nguyen; Cheryl L Day; Gregory K Robbins; Theresa Flynn; Katherine McGowan; Eric S Rosenberg; Michaela Lucas; Paul Klenerman; Raymond T Chung; Bruce D Walker
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia.

Authors:  Anke R M Olbrich; Simone Schimmer; Ulf Dittmer
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 8.  No one is naive: the significance of heterologous T-cell immunity.

Authors:  Raymond M Welsh; Liisa K Selin
Journal:  Nat Rev Immunol       Date:  2002-06       Impact factor: 53.106

9.  Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells.

Authors:  Adam P Kohm; Jeffrey S McMahon; Joseph R Podojil; Wendy Smith Begolka; Mathew DeGutes; Deborah J Kasprowicz; Steven F Ziegler; Stephen D Miller
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

10.  Cytotoxic T cells are elicited during acute infection of mice with lactate dehydrogenase-elevating virus but disappear during the chronic phase of infection.

Authors:  C Even; R R Rowland; P G Plagemann
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  52 in total

Review 1.  Influence of microbial environment on autoimmunity.

Authors:  Alexander V Chervonsky
Journal:  Nat Immunol       Date:  2009-12-17       Impact factor: 25.606

2.  CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells.

Authors:  Shelly J Robertson; Ronald J Messer; Aaron B Carmody; Robert S Mittler; Christopher Burlak; Kim J Hasenkrug
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

3.  Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points.

Authors:  Kirsten K Dietze; Gennadiy Zelinskyy; Kathrin Gibbert; Simone Schimmer; Sandra Francois; Lara Myers; Tim Sparwasser; Kim J Hasenkrug; Ulf Dittmer
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

4.  Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice.

Authors:  Norman Woller; Sarah Knocke; Bettina Mundt; Engin Gürlevik; Nina Strüver; Arnold Kloos; Bita Boozari; Peter Schache; Michael P Manns; Nisar P Malek; Tim Sparwasser; Lars Zender; Thomas C Wirth; Stefan Kubicka; Florian Kühnel
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

5.  Activated CD8+ T cells induce expansion of Vβ5+ regulatory T cells via TNFR2 signaling.

Authors:  Jara J Joedicke; Lara Myers; Aaron B Carmody; Ronald J Messer; Harald Wajant; Karl S Lang; Philipp A Lang; Tak W Mak; Kim J Hasenkrug; Ulf Dittmer
Journal:  J Immunol       Date:  2014-08-06       Impact factor: 5.422

6.  Toll-like receptor 7 inhibits early acute retroviral infection through rapid lymphocyte responses.

Authors:  Edward P Browne
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

7.  Myd88 is required for an antibody response to retroviral infection.

Authors:  Edward P Browne; Dan R Littman
Journal:  PLoS Pathog       Date:  2009-02-13       Impact factor: 6.823

8.  IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3.

Authors:  Michael S Harper; Bradley S Barrett; Diana S Smith; Sam X Li; Kathrin Gibbert; Ulf Dittmer; Kim J Hasenkrug; Mario L Santiago
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

9.  Race between retroviral spread and CD4+ T-cell response determines the outcome of acute Friend virus infection.

Authors:  Rebecca Pike; Andrew Filby; Mickaël J-Y Ploquin; Urszula Eksmond; Rute Marques; Inês Antunes; Kim Hasenkrug; George Kassiotis
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

Review 10.  Humoral immunity in the Friend retrovirus infection model.

Authors:  Kalani Halemano; Michael S Harper; Kejun Guo; Sam X Li; Karl J Heilman; Bradley S Barrett; Mario L Santiago
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.